TCR Engineered T-Cells are coming out of the shadows and into the light

The next two years will give definitive clues about the prospects of this promising treatment modality for solid tumors STUTTGART, Germany I May 23, 2018 I T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cuttingedge of adoptive T-cell therapy. Both receptors deploy T-cells to target the tumor, but...

Druggability of intracellular targets: a challenging, but highly rewarded goal for emerging technologies to generate TCR fusion proteins, TCRL antibodies and cell-penetrating biologics

STUTTGART, Germany I January 25, 2018 I A tissue-based map of the human proteome suggests that about 75 % are intracellular or secreted targets not accessible for conventional monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy (Uhlen et al., Science, 2015). Thus, the large pool of intracellular protein targets,...